{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:29:24Z","timestamp":1791559764366,"version":"4.3.4"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07596-8","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T11:55:24Z","timestamp":1767700524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine"],"prefix":"10.1186","volume":"24","author":[{"given":"Danial A","family":"Malik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.S","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Genova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremey","family":"Gaskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5537-3387","authenticated-orcid":false,"given":"Robert C.G.","family":"Martin II","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"7596_CR1","unstructured":"National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer, Surveillance, Epidemiology, and End Results Program (SEER). Bethesda, MD: National Cancer Institute; 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html."},{"key":"7596_CR2","unstructured":"Howlader N, N.A., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975\u20132017. Bethesda, MD: National Cancer Institute; 2020. p. 1975\u20132017. https:\/\/seer.cancer.gov\/csr\/1975_2017\/."},{"issue":"11","key":"7596_CR3","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"issue":"1","key":"7596_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, et al. The KRAS(G12C) inhibitor MRTX849 provides Insight toward therapeutic susceptibility of KRAS-Mutant Cancers in mouse models and patients. Cancer Discov. 2020;10(1):54\u201371.","journal-title":"Cancer Discov"},{"key":"7596_CR5","doi-asserted-by":"crossref","unstructured":"Budka J, et al. Design, Synthesis, and antitumor evaluation of an opioid growth factor bioconjugate Targeting pancreatic ductal adenocarcinoma. Pharmaceutics. 2024;16(2).","DOI":"10.3390\/pharmaceutics16020283"},{"issue":"6","key":"7596_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s13402-023-00836-3","volume":"46","author":"G Chen","year":"2023","unstructured":"Chen G, et al. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Cell Oncol (Dordr). 2023;46(6):1691\u2013708.","journal-title":"Cell Oncol (Dordr)"},{"issue":"6","key":"7596_CR7","doi-asserted-by":"publisher","first-page":"e17194","DOI":"10.1016\/j.heliyon.2023.e17194","volume":"9","author":"J Qiu","year":"2023","unstructured":"Qiu J, et al. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-\u03baB pathway. Heliyon. 2023;9(6):e17194.","journal-title":"Heliyon"},{"key":"7596_CR8","unstructured":"Wehling M, M.P., Zaninotto M, Lippi G, Marrer E, Dieterle F, Vonderscher J, Stroncek D, Jin P, Wang E, Ren J, Marincola FM, Kirchheiner J, Peeters W, Derksen WJM, de Kleijn DPV, Pasterkamp G, Grasso M, Bernardi D, Lind L, Azam F, Midgley R, Kerr DJ, Johansson L, Meyer-Lindenberg A, Tost H, Karlsson C, Ernst S, Boyer S, Platz S, Ferber G, Glimm E. In: Principles of translational science in medicine: from bench to bedside. Germany, Editor: R.-K.-U.H. Martin Wehling, Cambridge University Press; 2009."},{"key":"7596_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1479-5876-10-39","volume":"10","author":"A Wendler","year":"2012","unstructured":"Wendler A, Wehling M. Translatability scoring in drug development: eight case studies. J Transl Med. 2012;10:39.","journal-title":"J Transl Med"},{"issue":"3","key":"7596_CR10","doi-asserted-by":"publisher","first-page":"e1000245","DOI":"10.1371\/journal.pmed.1000245","volume":"7","author":"HB van der Worp","year":"2010","unstructured":"van der Worp HB, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7(3):e1000245.","journal-title":"PLoS Med"},{"issue":"11","key":"7596_CR11","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/nm.3973","volume":"21","author":"L Huang","year":"2015","unstructured":"Huang L, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med. 2015;21(11):1364\u201371.","journal-title":"Nat Med"},{"key":"7596_CR12","doi-asserted-by":"publisher","first-page":"115642","DOI":"10.1016\/j.addr.2025.115642","volume":"224","author":"J Gout","year":"2025","unstructured":"Gout J, et al. Pancreatic organoids as cancer avatars for true personalized medicine. Adv Drug Deliv Rev. 2025;224:115642.","journal-title":"Adv Drug Deliv Rev"},{"key":"7596_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3389\/fonc.2019.00875","volume":"9","author":"SI Choi","year":"2019","unstructured":"Choi SI, et al. Development of patient-derived preclinical platform for metastatic pancreatic cancer: PDOX and a subsequent organoid model System using percutaneous biopsy samples. Front Oncol. 2019;9:875.","journal-title":"Front Oncol"},{"key":"7596_CR14","doi-asserted-by":"crossref","unstructured":"Kang Y, et al. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest. 2022;132(24).","DOI":"10.1172\/JCI151604"},{"issue":"1","key":"7596_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4062\/biomolther.2023.109","volume":"32","author":"JH Lee","year":"2024","unstructured":"Lee JH, et al. Antiproliferative Activity of Piceamycin by regulating alpha-actinin-4 in gemcitabine-resistant pancreatic cancer cells. Biomol Ther (seoul). 2024;32(1):123\u201335.","journal-title":"Biomol Ther (seoul)"},{"issue":"1","key":"7596_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12935-023-02928-4","volume":"23","author":"K Yamakawa","year":"2023","unstructured":"Yamakawa K, et al. Blockage of retinoic acid signaling via RAR\u03b3 suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase. Cancer Cell Int. 2023;23(1):94.","journal-title":"Cancer Cell Int"},{"key":"7596_CR17","first-page":"216586","volume-title":"Single-cell transcriptome profiling of primary tumors and paired organoids of pancreatobiliary cancer","author":"K Chen","year":"2024","unstructured":"Chen K, et al. Single-cell transcriptome profiling of primary tumors and paired organoids of pancreatobiliary cancer. Cancer Lett. 2024;582:216586."},{"issue":"4","key":"7596_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1089\/nat.2023.0070","volume":"34","author":"L Wan","year":"2024","unstructured":"Wan L, et al. Screening splice-switching antisense oligonucleotides in pancreas-cancer organoids. Nucleic Acid Ther. 2024;34(4):188\u201398.","journal-title":"Nucleic Acid Ther"},{"issue":"9","key":"7596_CR19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112\u201329.","journal-title":"Cancer Discov"},{"issue":"6","key":"7596_CR20","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1242\/dev.150201","volume":"144","author":"M Huch","year":"2017","unstructured":"Huch M, et al. The hope and the hype of organoid research. Development. 2017;144(6):938\u201341.","journal-title":"Development"},{"issue":"5","key":"7596_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/ame2.12352","volume":"6","author":"M Gong","year":"2023","unstructured":"Gong M, et al. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy. Anim Model Exp Med. 2023;6(5):409\u201318.","journal-title":"Anim Model Exp Med"},{"issue":"1","key":"7596_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13046-022-02519-7","volume":"41","author":"S Schuth","year":"2022","unstructured":"Schuth S, et al. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. J Exp Clin Cancer Res. 2022;41(1):312.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"7596_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/SLA.0000000000004200","volume":"272","author":"TT Sepp\u00e4l\u00e4","year":"2020","unstructured":"Sepp\u00e4l\u00e4 TT, et al. Patient-derived organoid pharmacotyping is a clinically tractable strategy for precision medicine in pancreatic cancer. Ann Surg. 2020;272(3):427\u201335.","journal-title":"Ann Surg"},{"key":"7596_CR24","unstructured":"Larsen BM, et al. A pan-cancer organoid platform for precision medicine. Cell Rep. 2021;36(4)."},{"issue":"23","key":"7596_CR25","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1158\/1078-0432.CCR-21-1681","volume":"27","author":"EA Farshadi","year":"2021","unstructured":"Farshadi EA, et al. Organoids derived from neoadjuvant FOLFIRINOX patients recapitulate therapy resistance in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2021;27(23):6602\u201312.","journal-title":"Clin Cancer Res"},{"key":"7596_CR26","doi-asserted-by":"crossref","unstructured":"Armstrong A, et al. Multiplex patient-based drug response assay in pancreatic ductal adenocarcinoma. Biomedicines. 2021;9(7).","DOI":"10.3390\/biomedicines9070705"},{"key":"7596_CR27","doi-asserted-by":"crossref","unstructured":"Beutel AK, et al. A prospective feasibility trial to challenge patient-derived pancreatic cancer organoids in predicting treatment response. Cancers (Basel). 2021;13(11).","DOI":"10.3390\/cancers13112539"},{"key":"7596_CR28","doi-asserted-by":"crossref","unstructured":"Okuno K, et al. Andrographis reverses gemcitabine resistance through regulation of ERBB3 and calcium signaling pathway in pancreatic ductal adenocarcinoma. Biomedicines. 2023;11(1).","DOI":"10.3390\/biomedicines11010119"},{"key":"7596_CR29","unstructured":"Genova G, et al. Bench to bedside: a systematic review and translational scoring framework of organoid models in pancreatic ductal adenocarcinoma. PROSPERO; 2025."},{"key":"7596_CR30","doi-asserted-by":"crossref","unstructured":"Aguilar EN, et al. Structural basis for multivalent MUC16 recognition and robust anti-pancreatic cancer activity of humanized antibody AR9.6. Mol Cancer Ther. 2024;23(6):836\u201353.","DOI":"10.1158\/1535-7163.MCT-23-0868"},{"key":"7596_CR31","doi-asserted-by":"crossref","unstructured":"An J, et al. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Transl Oncol. 2024;49:102109.","DOI":"10.1016\/j.tranon.2024.102109"},{"key":"7596_CR32","doi-asserted-by":"crossref","unstructured":"Boil\u00e8ve A, et al. Organoids for functional precision medicine in advanced pancreatic cancer. Gastroenterology. 2024;167(5):961\u201376.e13.","DOI":"10.1053\/j.gastro.2024.05.032"},{"key":"7596_CR33","doi-asserted-by":"crossref","unstructured":"Chen HD, et al. SMAD4 endows TGF-\u03b21-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. Acta Pharmacol Sin. 2024;45(4):844\u201356.","DOI":"10.1038\/s41401-023-01199-z"},{"key":"7596_CR34","doi-asserted-by":"crossref","unstructured":"Choi W, et al. Establishment of patient-derived organoids using ascitic or pleural fluid from cancer patients. Cancer Res Treat. 2023;55(4):1077\u201386.","DOI":"10.4143\/crt.2022.1630"},{"key":"7596_CR35","doi-asserted-by":"crossref","unstructured":"Co IL, et al. An engineered 3D Co-culture model of primary macrophages and patient-derived tumour cells to explore cellular responses in the graded hypoxic microenvironment of pancreatic cancer. 2023.","DOI":"10.1101\/2023.07.13.548899"},{"key":"7596_CR36","doi-asserted-by":"crossref","unstructured":"Dantes Z, et al. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. JCI Insight. 2020;5(15).","DOI":"10.1172\/jci.insight.137809"},{"key":"7596_CR37","doi-asserted-by":"crossref","unstructured":"Deben C, et al. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition. J Exp Clin Cancer Res. 2024;43(1):88.","DOI":"10.1186\/s13046-024-03012-z"},{"key":"7596_CR38","doi-asserted-by":"crossref","unstructured":"Deben C, et al. Development and validation of the normalized organoid growth rate (NOGR) metric in brightfield imaging-based assays. Commun Biol. 2024;7(1):1612.","DOI":"10.1038\/s42003-024-07329-5"},{"key":"7596_CR39","doi-asserted-by":"crossref","unstructured":"Demyan L, et al. Pancreatic cancer patient-derived organoids can predict response to neoadjuvant chemotherapy. Ann Surg. 2022;276(3):450\u201362.","DOI":"10.1097\/SLA.0000000000005558"},{"key":"7596_CR40","doi-asserted-by":"crossref","unstructured":"Desai A, et al. Molecular characterization and therapeutic opportunities in kras wildtype pancreatic ductal adenocarcinoma. Cancers (basel). 2024;16(10).","DOI":"10.3390\/cancers16101861"},{"key":"7596_CR41","doi-asserted-by":"crossref","unstructured":"Doffo J, et al. Noxa expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc Natl Acad Sci U S A. 2022;119(9).","DOI":"10.1073\/pnas.2105691119"},{"key":"7596_CR42","unstructured":"Dreyer SB, et al. Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology. 2021;160(1):362\u201377.e13."},{"key":"7596_CR43","doi-asserted-by":"crossref","unstructured":"Driehuis E, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci U S A. 2019;116(52):26580\u201390.","DOI":"10.1073\/pnas.1911273116"},{"key":"7596_CR44","doi-asserted-by":"crossref","unstructured":"Ferreira N, et al. OrganoIDNet: a deep learning tool for identification of therapeutic effects in PDAC organoid-PBMC co-cultures from time-resolved imaging data. Cell Oncol (Dordr). 2024.","DOI":"10.1007\/s13402-024-00958-2"},{"key":"7596_CR45","doi-asserted-by":"crossref","unstructured":"Fraunhoffer N, et al. Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer. Front Oncol. 2024;14.","DOI":"10.3389\/fonc.2024.1437200"},{"key":"7596_CR46","doi-asserted-by":"crossref","unstructured":"Gao M, et al. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Br J Cancer. 2019;120(1):88\u201396.","DOI":"10.1038\/s41416-018-0298-0"},{"key":"7596_CR47","doi-asserted-by":"crossref","unstructured":"Gao M, et al. Development of a Single-Cell technique to Increase yield and use of gastrointestinal cancer organoids for personalized medicine application. J Am Coll Surg. 2021;232(4):504\u201314.","DOI":"10.1016\/j.jamcollsurg.2020.11.009"},{"key":"7596_CR48","doi-asserted-by":"crossref","unstructured":"Gassl V, et al. Chemosensitivity of 3D pancreatic cancer organoids is not affected by transformation to 2D culture or switch to physiological culture medium. Cancers (Basel). 2022;14(22).","DOI":"10.3390\/cancers14225617"},{"key":"7596_CR49","doi-asserted-by":"crossref","unstructured":"Geyer M, et al. A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. Cell Death Discov. 2023;9(1):20.","DOI":"10.1038\/s41420-023-01334-z"},{"key":"7596_CR50","doi-asserted-by":"crossref","unstructured":"Go YH, et al. Modeling pancreatic cancer with patient-derived organoids integrating cancer-associated fibroblasts. Cancers (Basel). 2022;14(9).","DOI":"10.3390\/cancers14092077"},{"key":"7596_CR51","doi-asserted-by":"crossref","unstructured":"Goluba K, et al. Personalized PDAC chip with functional endothelial barrier for tumour biomarker detection: a platform for precision medicine applications. Mater Today Bio. 2024;29:101262.","DOI":"10.1016\/j.mtbio.2024.101262"},{"key":"7596_CR52","doi-asserted-by":"crossref","unstructured":"Grossman JE, et al. Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer. Clin Cancer Res. 2022;28(4):708\u201318.","DOI":"10.1158\/1078-0432.CCR-20-4116"},{"key":"7596_CR53","doi-asserted-by":"crossref","unstructured":"Gr\u00fctzmeier SE, et al. Validation of a novel EUS-FNB-Derived organoid Co-culture System for drug screening in patients with pancreatic cancer. Cancers (basel). 2023;15(14).","DOI":"10.3390\/cancers15143677"},{"key":"7596_CR54","doi-asserted-by":"crossref","unstructured":"Gulay KCM, et al. Dual inhibition of KRASG12D and Pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 2023;83(18):3001\u201312.","DOI":"10.1158\/0008-5472.CAN-23-1313"},{"key":"7596_CR55","doi-asserted-by":"crossref","unstructured":"Hadj Bachir E, et al. A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: first insight of the underlying mechanisms. Biol Cell. 2022;114(1):32\u201355.","DOI":"10.1111\/boc.202100003"},{"key":"7596_CR56","doi-asserted-by":"crossref","unstructured":"Hawkins HJ, et al. Examination of wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). PLoS One. 2024;19(4):e0298808.","DOI":"10.1371\/journal.pone.0298808"},{"key":"7596_CR57","doi-asserted-by":"crossref","unstructured":"Hennig A, et al. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. J Pathol. 2022;257(5):607\u201319.","DOI":"10.1002\/path.5906"},{"key":"7596_CR58","doi-asserted-by":"crossref","unstructured":"Hirt CK, et al. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy. Cell Genomics. 2022;2(2).","DOI":"10.1016\/j.xgen.2022.100095"},{"key":"7596_CR59","doi-asserted-by":"crossref","unstructured":"Hossan MS, et al. Spatial alignment of organoids tracking subclonal chemotherapy resistance in pancreatic and ampullary cancer. Bioeng (Basel). 2023;10(1).","DOI":"10.3390\/bioengineering10010091"},{"key":"7596_CR60","doi-asserted-by":"crossref","unstructured":"Hou S, et al. Advanced Development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening. SLAS Discov. 2018;23(6):574\u201384.","DOI":"10.1177\/2472555218766842"},{"key":"7596_CR61","doi-asserted-by":"crossref","unstructured":"Hsieh YY, et al. Integration of bioinformatics Resources reveals the therapeutic benefits of gemcitabine and Cell cycle intervention in SMAD4-deleted pancreatic ductal adenocarcinoma. Genes (Basel). 2019;10(10).","DOI":"10.3390\/genes10100766"},{"key":"7596_CR62","doi-asserted-by":"crossref","unstructured":"Huang L, et al. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI Insight. 2020;5(21).","DOI":"10.1172\/jci.insight.135544"},{"key":"7596_CR63","doi-asserted-by":"crossref","unstructured":"Huffman BM, et al. A phase I expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2023;29(24):5047\u201356.","DOI":"10.1158\/1078-0432.CCR-23-2005"},{"key":"7596_CR64","doi-asserted-by":"crossref","unstructured":"Jiang S, et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. J Exp Clin Cancer Res. 2023;42(1):199.","DOI":"10.1186\/s13046-023-02756-4"},{"key":"7596_CR65","doi-asserted-by":"crossref","unstructured":"Lai Benjamin FL, et al. Recapitulating pancreatic tumor microenvironment through synergistic use of patient organoids and organ-on-a-chip vasculature. Adv Funct Mater. 2020;30(48).","DOI":"10.1002\/adfm.202000545"},{"key":"7596_CR66","doi-asserted-by":"crossref","unstructured":"Le Compte M, et al. Uncovering the hidden threat: single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. 2023.","DOI":"10.1101\/2023.02.27.530080"},{"key":"7596_CR67","doi-asserted-by":"crossref","unstructured":"Lee JH, et al. Establishment of patient-derived pancreatic cancer organoids from endoscopic ultrasound-guided fine-needle aspiration biopsies. Gut Liver. 2022;16(4):625\u201336.","DOI":"10.5009\/gnl210166"},{"key":"7596_CR68","doi-asserted-by":"crossref","unstructured":"Li Y, et al. Metabolic classification suggests the GLUT1\/ALDOB\/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023;4(9):101162.","DOI":"10.1016\/j.xcrm.2023.101162"},{"key":"7596_CR69","doi-asserted-by":"crossref","unstructured":"Lumibao JC, et al. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids. JCI Insight. 2024;9(1).","DOI":"10.1172\/jci.insight.172419"},{"key":"7596_CR70","doi-asserted-by":"crossref","unstructured":"Matsumoto K, et al. Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction. J Gastroenterol. 2024;59(7):629\u201340.","DOI":"10.1007\/s00535-024-02103-0"},{"key":"7596_CR71","doi-asserted-by":"crossref","unstructured":"Mehnaz G, et al. Chemotherapy for pancreatic cancer can be optimized with the use of drug resistance testing using tissue organoids. Pak J Med And Health Sci. 16(10):891\u201393.","DOI":"10.53350\/pjmhs221610891"},{"key":"7596_CR72","doi-asserted-by":"crossref","unstructured":"Naumann M, et al. Combined systemic drug treatment with proton therapy: investigations on patient-derived organoids. Cancers (basel). 2022;14(15).","DOI":"10.3390\/cancers14153781"},{"key":"7596_CR73","doi-asserted-by":"crossref","unstructured":"Nicolle R, et al. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer. Transl Oncol. 2022;16:101315.","DOI":"10.1016\/j.tranon.2021.101315"},{"key":"7596_CR74","doi-asserted-by":"crossref","unstructured":"Nicolson NG, et al. Patient-derived organoid pharmacotyping as a predictive tool for therapeutic selection in pancreatic ductal adenocarcinoma. Ann Surg. 2024.","DOI":"10.1097\/SLA.0000000000006517"},{"issue":"3","key":"7596_CR75","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579\u201396.","journal-title":"J Exp Med"},{"key":"7596_CR76","doi-asserted-by":"crossref","unstructured":"Okuno K, et al. Berberine Overcomes Gemcitabine-Associated Chemoresistance through regulation of Rap1\/PI3K-Akt signaling in pancreatic ductal adenocarcinoma. Pharmaceuticals (Basel). 2022;15(10).","DOI":"10.3390\/ph15101199"},{"issue":"4","key":"7596_CR77","doi-asserted-by":"publisher","first-page":"e14876","DOI":"10.15252\/emmm.202114876","volume":"14","author":"K Peschke","year":"2022","unstructured":"Peschke K, et al. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Mol Med. 2022;14(4):e14876.","journal-title":"EMBO Mol Med"},{"issue":"25","key":"7596_CR78","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan S, et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021;184(25):6119\u201337.e 6126.","journal-title":"Cell"},{"key":"7596_CR79","doi-asserted-by":"publisher","first-page":"102786","DOI":"10.1016\/j.ebiom.2020.102786","volume":"56","author":"G Raimondi","year":"2020","unstructured":"Raimondi G, et al. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. EBioMedicine. 2020;56:102786.","journal-title":"EBioMedicine"},{"issue":"1","key":"7596_CR80","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1541-7786.MCR-18-0531","volume":"17","author":"I Romero-Calvo","year":"2019","unstructured":"Romero-Calvo I, et al. Human organoids share structural and genetic features with primary pancreatic adenocarcinoma tumors. Mol Cancer Res. 2019;17(1):70\u201383.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"7596_CR81","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41420-024-01871-1","volume":"10","author":"S Roy","year":"2024","unstructured":"Roy S, et al. SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids. Cell Death Discov. 2024;10(1):106.","journal-title":"Cell Death Discov"},{"key":"7596_CR82","doi-asserted-by":"crossref","unstructured":"Sarno F, et al. A phase iii randomized trial of integrated Genomics and avatar models for personalized treatment of pancreatic cancer: the avatar trial. Clin cancer Res. 2024.","DOI":"10.1158\/1078-0432.c.7631017"},{"issue":"1","key":"7596_CR83","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1038\/s41467-020-19058-4","volume":"11","author":"B Schuster","year":"2020","unstructured":"Schuster B, et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat Commun. 2020;11(1):5271.","journal-title":"Nat Commun"},{"issue":"15","key":"7596_CR84","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1158\/1078-0432.CCR-21-4165","volume":"28","author":"TT Sepp\u00e4l\u00e4","year":"2022","unstructured":"Sepp\u00e4l\u00e4 TT, et al. Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response. Clin Cancer Res. 2022;28(15):3296\u2013307.","journal-title":"Clin Cancer Res"},{"key":"7596_CR85","doi-asserted-by":"crossref","unstructured":"Shah VM, et al. Microfluidics formulated Liposomes of hypoxia activated prodrug for treatment of pancreatic cancer. Pharmaceutics. 2022;14(4).","DOI":"10.3390\/pharmaceutics14040713"},{"key":"7596_CR86","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fonc.2020.00553","volume":"10","author":"JT Sharick","year":"2020","unstructured":"Sharick JT, et al. Metabolic heterogeneity in patient tumor-derived organoids by primary site and drug treatment. Front Oncol. 2020;10:553.","journal-title":"Front Oncol"},{"key":"7596_CR87","doi-asserted-by":"publisher","first-page":"116598","DOI":"10.1016\/j.ejmech.2024.116598","volume":"275","author":"H Sharma","year":"2024","unstructured":"Sharma H, et al. Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. Eur J Med Chem. 2024;275:116598.","journal-title":"Eur J Med Chem"},{"key":"7596_CR88","doi-asserted-by":"publisher","first-page":"216650","DOI":"10.1016\/j.canlet.2024.216650","volume":"584","author":"S Steiner","year":"2024","unstructured":"Steiner S, et al. Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities. Cancer Lett. 2024;584:216650.","journal-title":"Cancer Lett"},{"key":"7596_CR89","doi-asserted-by":"crossref","unstructured":"Tang R, et al. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes antitumor immunity and chemo-response. Cell Rep Med. 2023;4(10).","DOI":"10.1016\/j.xcrm.2023.101234"},{"issue":"1","key":"7596_CR90","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13046-024-03201-w","volume":"43","author":"J Tao","year":"2024","unstructured":"Tao J, et al. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. J Exp Clin Cancer Res. 2024;43(1):277.","journal-title":"J Exp Clin Cancer Res"},{"key":"7596_CR91","volume-title":"KRAS(G) (12C)-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening","author":"C Tapia Contreras","year":"2024","unstructured":"Tapia Contreras C, et al. KRAS(G) (12C)-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Mol Oncol; 2024."},{"key":"7596_CR92","doi-asserted-by":"crossref","unstructured":"Tiriac H, et al. Isolation and characterization of patient-derived pancreatic ductal adenocarcinoma organoid models. J Vis Exp(155). 2020.","DOI":"10.3791\/60364"},{"issue":"1","key":"7596_CR93","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12885-018-4238-4","volume":"18","author":"S Tsai","year":"2018","unstructured":"Tsai S, et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer. 2018;18(1):335.","journal-title":"BMC Cancer"},{"issue":"6","key":"7596_CR94","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/MPA.0000000000000543","volume":"45","author":"AJ Walsh","year":"2016","unstructured":"Walsh AJ, et al. Optical imaging of drug-induced metabolism changes in murine and human pancreatic cancer organoids reveals heterogeneous drug response. Pancreas. 2016;45(6):863\u201369.","journal-title":"Pancreas"},{"issue":"1","key":"7596_CR95","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12885-022-09619-9","volume":"22","author":"S Watanabe","year":"2022","unstructured":"Watanabe S, et al. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer. BMC Cancer. 2022;22(1):489.","journal-title":"BMC Cancer"},{"issue":"13","key":"7596_CR96","doi-asserted-by":"publisher","first-page":"109291","DOI":"10.1016\/j.celrep.2021.109291","volume":"35","author":"AM Waters","year":"2021","unstructured":"Waters AM, et al. Targeting p130Cas- and microtubule-dependent myc regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep. 2021;35(13):109291.","journal-title":"Cell Rep"},{"issue":"19","key":"7596_CR97","doi-asserted-by":"publisher","first-page":"14764","DOI":"10.18632\/oncotarget.24483","volume":"9","author":"RA Wolff","year":"2018","unstructured":"Wolff RA, et al. Dynamic changes during the treatment of pancreatic cancer. Oncotarget. 2018;9(19):14764\u201390.","journal-title":"Oncotarget"},{"key":"7596_CR98","doi-asserted-by":"crossref","unstructured":"Xiao M, et al. TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality. Gut. 2024.","DOI":"10.1136\/gutjnl-2024-332782"},{"issue":"42","key":"7596_CR99","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.3748\/wjg.v30.i42.4532","volume":"30","author":"JL Yang","year":"2024","unstructured":"Yang JL, et al. Strategic insights into the cultivation of pancreatic cancer organoids from endoscopic ultrasonography-guided biopsy tissue. World J Gastroenterol. 2024;30(42):4532\u201343.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"7596_CR100","doi-asserted-by":"publisher","first-page":"200769","DOI":"10.1016\/j.omton.2024.200769","volume":"32","author":"JG Yuen","year":"2024","unstructured":"Yuen JG, et al. Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma. Mol Ther Oncol. 2024;32(1):200769.","journal-title":"Mol Ther Oncol"},{"key":"7596_CR101","doi-asserted-by":"publisher","first-page":"215922","DOI":"10.1016\/j.canlet.2022.215922","volume":"551","author":"C Zhang","year":"2022","unstructured":"Zhang C, et al. Small molecule inhibitor against onco-mucins disrupts Src\/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Cancer Lett. 2022;551:215922.","journal-title":"Cancer Lett"},{"issue":"18","key":"7596_CR102","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1042\/CS20240450","volume":"138","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, et al. PDCD10 promotes the tumor-supporting functions of TGF-\u03b2 in pancreatic cancer. Clin Sci (Lond). 2024;138(18):1111\u201329.","journal-title":"Clin Sci (lond)"},{"issue":"1","key":"7596_CR103","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-023-02671-8","volume":"42","author":"T Zhou","year":"2023","unstructured":"Zhou T, et al. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo\/YAP1\/c-jun axis. J Exp Clin Cancer Res. 2023;42(1):111.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"7596_CR104","doi-asserted-by":"publisher","first-page":"25468","DOI":"10.1038\/s41598-024-75888-y","volume":"14","author":"EA Farshadi","year":"2024","unstructured":"Farshadi EA, et al. Tumor organoids improve mutations detection on pancreatic ductal adenocarcinoma. Sci Rep. 2024;14(1):25468.","journal-title":"Sci Rep"},{"issue":"4","key":"7596_CR105","first-page":"584","volume":"40","author":"E VandeWall","year":"2023","unstructured":"VandeWall E, et al. Organoids in translational oncology: predictive power and practical implementation. ALTEX. 2023;40(4):584\u201394.","journal-title":"ALTEX"},{"issue":"15","key":"7596_CR106","first-page":"6604","volume":"67","author":"JH Lee","year":"2007","unstructured":"Lee JH, et al. Involvement of Cdk1\/cyclin B1 in G2\/M checkpoint in response to ionizing radiation. Cancer Res. 2007;67(15):6604\u201310.","journal-title":"Cancer Res"},{"issue":"1","key":"7596_CR107","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/molecules27010019","volume":"27","author":"C Pecoraro","year":"2021","unstructured":"Pecoraro C, Parrino B, Cascioferro S, Puerta A, Avan A, Peters GJ, Diana P, Giovannetti E, Carbone D. A new oxadiazole-based topsentin derivative modulates cyclin-dependent kinase 1 expression and exerts cytotoxic effects on pancreatic cancer cells. Molecules. 2021;27(1):19.","journal-title":"Molecules"},{"key":"7596_CR108","unstructured":"U.S. Food and Drug Administration. FDA announces plan to phase out animal testing requirement for monoclonal antibodies and other drugs. FDA press release. Retrieved from 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs."},{"issue":"2","key":"7596_CR109","first-page":"114","volume":"6","author":"IW Mak","year":"2014","unstructured":"Mak IW, et al. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114\u201318.","journal-title":"Am J Transl Res"},{"key":"7596_CR110","doi-asserted-by":"crossref","unstructured":"Hennig A, et al. CFTR expression analysis for subtyping of human pancreatic cancer organoids. Stem Cells Int. 2019;2019:1024614.","DOI":"10.1155\/2019\/1024614"},{"issue":"17","key":"7596_CR111","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.3390\/cancers13174389","volume":"13","author":"R Wijnen","year":"2021","unstructured":"Wijnen R, et al. Cyclin dependent kinase-1 (CDK-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (PDAC). Cancers. 2021;13(17):4389.","journal-title":"Cancers"},{"key":"7596_CR112","unstructured":"National Institutes of Health. NIH to prioritize human-based research technologies. NIH News release. Retrieved from 2024. https:\/\/www.nih.gov\/news-events\/news-releases\/nih-prioritize-human-based-research-technologies."},{"issue":"9","key":"7596_CR113","doi-asserted-by":"publisher","first-page":"E713","DOI":"10.1001\/amajethics.2024.7","volume":"26","author":"AG Martinez","year":"2024","unstructured":"Martinez AG. What should we replace nonhuman animals in biomedical research protocols with? AMA J Ethics. 2024;26(9):E713\u201321. https:\/\/doi.org\/10.1001\/amajethics.2024.7.","journal-title":"AMA J Ethics"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07596-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:04:03Z","timestamp":1770131043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07596-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7596"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07596-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}